Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Tandem Diabetes Care, Inc.
TNDM
NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.1B
$15.32
▼ -2.73%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$9.98 - $29.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 10.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Advanced AI-powered insulin delivery algorithms (Basal-IQ, Control IQ) reducing hypoglycemic events
- Integrated ecosystem connecting pumps, CGM, and digital platforms for seamless data flow
- Strategic partnerships with Dexcom and Abbott providing competitive moat in device interoperability
- Strong brand loyalty and user satisfaction in insulin pump market
- Recurring revenue model through consumable cartridges and infusion sets
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Expanding global market penetration beyond United States into international markets
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Weak
-17.7% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TNDM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 28, 2026
MAY 7, 2026
Reported EPS of -$0.30 vs -$0.46 consensus (+34.8% surprise). Revenue of $247.2M vs $240.4M expected (+2.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+34.8%
Next: Apr 28, 2026
Revenue trend · last 8Q
—
—
+44%
+22%
+8%
-31%
+3%
+5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$221.9M
$363.3M
$282.6M
$234.4M
$240.7M
$249.3M
$290.4M
$247.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-8.3%
Wall Street consensus
13 analysts · 38% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
38%
Hold
62%
Sell
0%
Median Price Target
$27.00
▲ +76.2% vs $15.32
Latest: Deutsche Bank · Jun 23, 2026
5 analysts covering